AU2002220404A1 - Method for treating thrombocytopenia with monoclonal ivig - Google Patents
Method for treating thrombocytopenia with monoclonal ivigInfo
- Publication number
- AU2002220404A1 AU2002220404A1 AU2002220404A AU2040402A AU2002220404A1 AU 2002220404 A1 AU2002220404 A1 AU 2002220404A1 AU 2002220404 A AU2002220404 A AU 2002220404A AU 2040402 A AU2040402 A AU 2040402A AU 2002220404 A1 AU2002220404 A1 AU 2002220404A1
- Authority
- AU
- Australia
- Prior art keywords
- ivig
- monoclonal
- treating thrombocytopenia
- thrombocytopenia
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
The present invention relates to a method and composition utilizing monoclonal intravenous immunoglobulin (mlVIG) for increasing platelet cell counts in thrombocytopenia The method and composition are suitable for treatments of patients suffering from medical conditions, such as idiopathic thrombocytopenic purpura (ITP) which result in low platelet cell numbers
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24944100P | 2000-11-20 | 2000-11-20 | |
US60/249,441 | 2000-11-20 | ||
PCT/CA2001/001648 WO2002040047A2 (en) | 2000-11-20 | 2001-11-20 | Method for treating thrombocytopenia with monoclonal ivig |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002220404A1 true AU2002220404A1 (en) | 2002-05-27 |
Family
ID=22943488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002220404A Abandoned AU2002220404A1 (en) | 2000-11-20 | 2001-11-20 | Method for treating thrombocytopenia with monoclonal ivig |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040047862A1 (en) |
EP (2) | EP2283861B1 (en) |
AT (1) | ATE540694T1 (en) |
AU (1) | AU2002220404A1 (en) |
CA (2) | CA2856033C (en) |
DK (2) | DK1370288T3 (en) |
WO (1) | WO2002040047A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0314461D0 (en) * | 2003-06-20 | 2003-07-23 | Isis Innovation | Suppression of transplant rejection |
DK1737487T3 (en) * | 2004-03-30 | 2016-08-22 | Canadian Blood Services | Process for the treatment of autoimmune diseases with antibodies |
US8470318B2 (en) | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
US8597636B2 (en) | 2006-01-13 | 2013-12-03 | Canadian Blood Services | Method for treating autoimmune diseases and compositions therefor |
MX2008012843A (en) | 2006-04-05 | 2009-01-19 | Univ Rockefeller | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods. |
US7846744B2 (en) | 2008-04-22 | 2010-12-07 | Ravetch Jeffrey V | Methods of identifying anti-inflammatory compounds |
US20150329639A1 (en) * | 2012-12-12 | 2015-11-19 | University Of Virginia Patent Foundation | Compositions and methods for regulating erythropoiesis |
ES2742682T3 (en) | 2013-12-24 | 2020-02-17 | Argenx Bvba | FCRN antagonists and methods of use |
EP3268391B1 (en) | 2015-03-09 | 2021-08-11 | argenx BVBA | Methods of reducing serum levels of fc-containing agents using fcrn antagonsits |
GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
MX2021014756A (en) | 2019-06-07 | 2022-01-18 | Argenx Bvba | PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION. |
EP4087875A1 (en) | 2020-01-08 | 2022-11-16 | Argenx BV | Methods for treating pemphigus disorders |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5993812A (en) * | 1995-09-14 | 1999-11-30 | Cangene Corporation | Method of delaying the progression of an infection with the human immunodeficiency virus |
JPH0987202A (en) * | 1995-09-20 | 1997-03-31 | Sumitomo Pharmaceut Co Ltd | Blood coagulation abnormality therapeutic agent |
AU8266798A (en) * | 1997-06-27 | 1999-01-19 | Biogen, Inc. | Cd154 blockade therapy for autoimmune diseases |
US5980893A (en) * | 1997-07-17 | 1999-11-09 | Beth Israel Deaconess Medical Center, Inc. | Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis |
CA2904259C (en) * | 1999-05-07 | 2016-11-15 | Genentech, Inc. | Use of rituximab to treat vasculitis |
US20030095966A1 (en) * | 2000-03-29 | 2003-05-22 | Yang Liu | Method of blocking tissue destruction by autoreactive T cells |
JP2004508420A (en) * | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | Combination therapy for treating autoimmune diseases using B cell depleting antibody / immunomodulatory antibody combination |
AUPR540301A0 (en) * | 2001-06-01 | 2001-06-28 | Walter And Eliza Hall Institute Of Medical Research, The | A method of purification of cells |
-
2001
- 2001-11-20 AT AT01996390T patent/ATE540694T1/en active
- 2001-11-20 CA CA2856033A patent/CA2856033C/en not_active Expired - Lifetime
- 2001-11-20 CA CA2467781A patent/CA2467781C/en not_active Expired - Lifetime
- 2001-11-20 DK DK01996390.9T patent/DK1370288T3/en active
- 2001-11-20 EP EP10178480.9A patent/EP2283861B1/en not_active Expired - Lifetime
- 2001-11-20 US US10/432,442 patent/US20040047862A1/en not_active Abandoned
- 2001-11-20 DK DK10178480.9T patent/DK2283861T3/en active
- 2001-11-20 EP EP01996390A patent/EP1370288B1/en not_active Expired - Lifetime
- 2001-11-20 WO PCT/CA2001/001648 patent/WO2002040047A2/en not_active Application Discontinuation
- 2001-11-20 AU AU2002220404A patent/AU2002220404A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2283861A3 (en) | 2013-05-29 |
US20040047862A1 (en) | 2004-03-11 |
WO2002040047A3 (en) | 2003-10-02 |
EP2283861B1 (en) | 2016-01-27 |
EP1370288A2 (en) | 2003-12-17 |
WO2002040047A2 (en) | 2002-05-23 |
EP2283861A2 (en) | 2011-02-16 |
DK2283861T3 (en) | 2016-02-15 |
CA2467781C (en) | 2014-09-23 |
ATE540694T1 (en) | 2012-01-15 |
DK1370288T3 (en) | 2012-03-05 |
EP1370288B1 (en) | 2012-01-11 |
CA2856033A1 (en) | 2002-05-23 |
CA2856033C (en) | 2015-11-03 |
CA2467781A1 (en) | 2002-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002220404A1 (en) | Method for treating thrombocytopenia with monoclonal ivig | |
NZ568403A (en) | CD20-specific antibodies and methods of employing same | |
WO2003057857A3 (en) | Antibodies directed to pdgfd and uses thereof | |
SG170110A1 (en) | Identification and engineering of antibodies with variant heavy chains and methods of using same | |
TW200716677A (en) | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders | |
NZ603883A (en) | Method for preparing antibodies having improved properties | |
WO2002072605A3 (en) | Expression technology for proteins containing a hybrid isotype antibody moiety | |
WO2004070011A3 (en) | HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES | |
WO2004016769A3 (en) | Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof | |
SG156547A1 (en) | Human monoclonal antibodies to ctla-4 | |
NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
WO2006055638A3 (en) | Fully human monoclonal antibodies to il-13 | |
EP1594441A4 (en) | Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same | |
TW200637873A (en) | Antibodies against interleukin-1 beta | |
MX2009005743A (en) | NEW Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES. | |
NZ595011A (en) | Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases | |
TW200634027A (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
IL148079A0 (en) | Human ctla-4 antibodies and compositions containing the same | |
NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
WO2005000194A3 (en) | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same | |
DE60328747D1 (en) | Purification of polyreactive autoantibodies and their uses | |
WO2002015846A3 (en) | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders | |
GB0309126D0 (en) | Clostridium difficile focussed antibodies | |
WO2005023201A3 (en) | Methods for treating rheumatoid arthritis | |
RU2019103991A (en) | ANTI-IL-22R-ANTIBODY |